New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:48 EDTPCYC, ABTPharmacyclics shares have 90% upside potential, says Deutsche Bank
Deutsche Bank believes shares of Pharmacyclics (PCYC) have 90% upside potential over the next 12 months following the recent pullback. Deutsche attributes to the recent pullback to fears around Abbott's (ABT) data for ABT199 at ASCO and weekly scripts that came in lower than some investor expectations. The firm has a Buy rating on Pharmacyclics with a $180 price target.
News For PCYC;ABT From The Last 14 Days
Check below for free stories on PCYC;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:23 EDTABTGoldman to hold a conference
Subscribe for More Information
12:50 EDTABTEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 26, 2014
07:35 EDTPCYCPharmacyclics Imbruvica.checks positive, says Deutsche Bank
Subscribe for More Information
August 19, 2014
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information
August 18, 2014
16:08 EDTPCYCPharmacyclics names Shawn Cline Tomasello as Chief Commercial Officer
Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4B in revenue. Prior to joining Celgene, Cline Tomasello was the National Director of Hematology for Rituxan at Genentech, where she was responsible for over $1.7B in revenue.
09:00 EDTABTAbbott and Defense Department to develop portable blood tests
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use